UPDATE: Cancer Programme IPP-20410613th August 2013 - 10:01 am
ImmuPharma plc (LSE:IMM) (“Immupharma” or the “Company” or the “Group”), the specialist drug discovery and development company is pleased to provide an update on its lead cancer programme IPP-204106.
As announced in September last year the Company commenced dosing in cancer patients with the next generation of the “polyplexed Nucant” (See notes to editors).
Three hospitals are conducting these trials designed to assess safety and dosing levels in Europe including the prestigious Institute Jules Bordet, an Integrated Multidisciplinary Centre which is the only autonomous hospital in Belgium totally dedicated to cancer.
The trial is progressing according to protocol and its objective is to identify the optimal dose for treating patients. The oncologists involved in the study are leading the decisions on the number of patients and the dosing regimen. Patients that are being enrolled in this trial are in a serious condition, suffering from a range of cancers, all have metastasis (tumour spreading) and have failed their previous treatment. This trial will be followed by a Phase II efficacy study designed to treat various cancers, in approximately 30 patients, to identify appropriate biomarkers.
Our further intention is to conduct more focused follow-up studies on patients with glioblastoma (brain tumour), metastatic melanoma, and pancreatic cancer where nucleolin plays a key role and who are showing the appropriate biomarkers.
Dr Robert Zimmer, MD, PhD, ImmuPharma’s President and Chief Scientific Officer commented: “The clinical development of our cancer programme continues to be a key priority for ImmuPharma. We look forward to announcing interim results from the current trial in the near future.”